Literature DB >> 19114306

Small-molecule perturbation of competing interactions between c-Myc and Max.

Ariele Viacava Follis1, Dalia I Hammoudeh, Andrew T Daab, Steven J Metallo.   

Abstract

The oncogenic transcription factor c-Myc undergoes coupled binding and folding of its basic-helix-loop-helix-leucine zipper domain (bHLHZip) upon heterodimerization with its partner protein Max. The latter exists in two isoforms: p21, which homodimerizes poorly, and p22, which homodimerizes well. We show that the effect of 10058-F4 (a small-molecule that binds disordered c-Myc monomers and disrupts the c-Myc-Max complex) on both c-Myc-Max heterodimerization and DNA binding is dependent on the nature of the Max isoform. In the presence of p22 Max the effective inhibitor concentration is lower than in the presence of p21 Max, as the p22 Max homodimer formation affects the thermodynamics by competing against the c-Myc-Max heterodimerization event.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19114306     DOI: 10.1016/j.bmcl.2008.12.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

Review 1.  Understanding protein non-folding.

Authors:  Vladimir N Uversky; A Keith Dunker
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 2.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

3.  Expanding the proteome: disordered and alternatively folded proteins.

Authors:  H Jane Dyson
Journal:  Q Rev Biophys       Date:  2011-07-01       Impact factor: 5.318

Review 4.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

5.  Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.

Authors:  Jason P W Carey; Cansu Karakas; Tuyen Bui; Xian Chen; Smruthi Vijayaraghavan; Yang Zhao; Jing Wang; Keith Mikule; Jennifer K Litton; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

Review 6.  A complex task? Direct modulation of transcription factors with small molecules.

Authors:  Angela N Koehler
Journal:  Curr Opin Chem Biol       Date:  2010-04-13       Impact factor: 8.822

Review 7.  Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept.

Authors:  Vladimir N Uversky
Journal:  Expert Rev Proteomics       Date:  2010-08       Impact factor: 3.940

Review 8.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

9.  In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.

Authors:  Dana M Clausen; Jianxia Guo; Robert A Parise; Jan H Beumer; Merrill J Egorin; John S Lazo; Edward V Prochownik; Julie L Eiseman
Journal:  J Pharmacol Exp Ther       Date:  2010-08-26       Impact factor: 4.030

10.  A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

Authors:  Huabo Wang; Anand Ramakrishnan; Steven Fletcher; Edward V Prochownik
Journal:  J Biol Methods       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.